Clinical Trial Update: Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describing the investigation of combining tisagenlecleucel with ibrutinib for mantle cell lymphoma, currently active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Kymriah (tisagenlecleucel)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Mantle Cell Lymphoma Recurrent | Phase 2 | Status: ACTIVE_NOT_RECRUITING